Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section
Diagnostic Accuracy of Combined Perfusion Index, Internal Jugular Vein Collapsibility Index and Cardiac Index in Predicting Post-Spinal Hypotension During Elective Cesarean Section: A Prospective Randomized Study
compare Perfusion Index with Internal Jugular Vein Collapsibility Index (IJVCI) as a predictor for post-spinal hypotension in parturient undergoing elective caesarean section.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
- Pre-anesthetic evaluation (History-Investigation - Examination) the day before surgery.
- NPO: 8 hours for solids, 2 hours for clear fluids.
- Pre-medication: Ranitidine 50 mg IV + Metoclopramide 10 mg IV, 30 minutes before anesthesia.
- 18-G IV cannula in the non-dominant forearm.
- Standard monitoring in the operating room: pulse oximetry (SpO2), NIBP, and ECG.
- Baseline measurements (HR, SBP, DBP, MAP, SpO2, PI, CI, IJVCI) recorded in the supine position with 15 degree left lateral tilt.
- All indicators will be measured in a single group before spinal anesthesia and comparisons will be made for the most sensitive maneuver in prediction of post spinal hypotension.
- Cardiac Index (CI) will be measured using cardiometry before spinal anesthesia.
- Perfusion Index (PI) is measured (Three consecutive readings are recorded at 1-minute intervals, will be repeated with another reading after delivery of baby).• The cut-off applied is: -
- 3.5 or less (low risk for hypotension)
- Greater than 3.5 (high risk for hypotension)
- Internal Jugular Vein Collapsibility Index will be measured by Ultrasonographic assessment and is performed by using a 6-10 MHz linear ultrasound probe. (The patient is placed supine with 15 degree left lateral tilt, The probe is positioned horizontally at the right side of the neck at the level of the middle thyroid cartilage, obtaining a transverse view of the right IJV. M-mode imaging during both spontaneous and deep breathing).
- Anteroposterior diameters of the IJV were estimated during the respiratory cycle. The IJV collapsibility index (IJVCI) was estimated via the following equation: Maximum diameter - lowest diameter/maximum diameter) 100% .
- The mean of three consecutive measurements is recorded for each breathing mode in quite respiratory cycle.
- Images will be saved for offline analysis.
- The cut-off applied is:
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after spinal anesthesia in CS.
- Spinal anesthesia with intrathecal drug regimen 10-12 mg of 0.5% hyperbaric bupivacaine plus 25 micrograms (mic) Fentanyl].
- Co-loading with Ringer's lactate at 10ml/Kg will be administrated, along with spinal anesthesia placement .Data Collection
Baseline:
- Patient demographic data (age, ASA physical status, comorbidities, current medications, and BMI).
- Hemodynamics (Heart rate- Mean Arterial Blood Pressure - Systolic Blood Pressure -Oxygen Saturation) baseline reading before induction of spinal anesthesia.
- Preoperative IJVCI measurement by ultrasound imaging in supine position.
- Preoperative Perfusion Index reading.
- Preoperative Cardiac index reading.
Intraoperative:
-
Hemodynamic parameters (SBP, DBP, MAP, HR, SpO2) are recorded: -
- Every 1 minute for the first 10 minutes,
- Every 3 minutes until delivery,
- Every 5 minutes thereafter until end of surgery.
-
Total phenylephrine dose in microgram & Total Ephedrine dose (mg) [if persistent hypotension].
-
Total IV fluid volume (mL)
-
Total Blood loss (mL)
-
Total Urine output (mL)
-
Time from spinal block to delivery (min)
-
Total time of surgery.
-
All adverse events (nausea, vomiting, hypotension, bradycardia, oxygen desaturation) are recorded throughout.
Definition of Outcomes All outcome definitions are pre-specified and uniformly applied across all patients: -
- Post-spinal hypotension: A fall in systolic blood pressure (SBP) below 90 mmHg.
- Episodes are recorded from the time of spinal injection until delivery of the baby.
- Bradycardia: Heart rate below 50 beats per minute requiring pharmacological treatment with atropine 0.01 mg/kg IV.
Treatment of PSH
- First-line: 200 mL Ringer's lactate rapid IV infusion.
- If SBP remains below 90 mmHg phenylephrine 25-100 microgram if persistent hypotension gives Ephedrine 5-15 mg IV bolus.
- Bradycardia (HR < 50 bpm): Atropine 0.01 mg/kg IV.
- All vasopressor doses and additional fluid volumes administered are recorded.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Nevine Soliman, MD
- Número de teléfono: 201128861471
- Correo electrónico: mostafanevine@gmail.com
Ubicaciones de estudio
-
-
-
Alexandria, Egipto
- Reclutamiento
- Menoufia University,Faculty of Medicine
-
Contacto:
- Nevine Soliman, MD
- Número de teléfono: 201128861471
- Correo electrónico: mostafanevine@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults undergoing Elective Cesarean Section at Menoufia University Hospitals
Descripción
Inclusion Criteria:
-
Full-term pregnant women undergoing elective cesarean section under spinal anesthesia (gestational age >= 37 weeks), singleton pregnancy.
- Age: 18-40 years.
- ASA I, II.
- BMI: 18.5-35 kg/m2.
Exclusion Criteria:
-
• Patient refusal or inability to provide informed consent.
- Emergency cesarean section.
- Known contraindications to spinal anesthesia (coagulopathy, local infection, elevated ICP).
- Baseline hypotension (SBP < 100 mmHg) prior to spinal anesthesia.
- Hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia).
- Placenta previa or antepartum hemorrhage.
- Multiple pregnancy or known fetal abnormality.
- BMI > 35 kg/m2.
- Pre-existing cardiovascular, cerebrovascular, or significant pulmonary disease.
- Gestational diabetes or uncontrolled systemic disease.
- Hemoglobin < 8 g/dL or known haemoglobinopathy.
- Peripheral vascular disease affects pulse oximetry signal quality.
- More than two attempts at lumbar puncture or failed.
- Inadequate spinal block.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Perfusion Index (PI) group measured by pulse oximeter
|
is measured using a validated multi-parameter monitor with a pulse oximetry module (Mindray uMEC 12 or equivalent).
|
|
Internal Jugular Vein Collapsibility Index group will be measured by ultrasonography
IJVCI < 35-38% → lower risk of post-spinal hypotension IJVCI ≥ 38-40% → higher likelihood of hypotension after |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
compare the diagnostic accuracy assessed by ROC curve analysis between Perfusion Index (PI) & Internal Jugular Vein Collapsibility Index (IJVCI) combined with Cardiac Index (CI) in predicting post-spinal hypotension in elective CS patients.
Periodo de tiempo: • Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
• Three consecutive readings are recorded at 1-minute intervals. • These steps will be repeated with another reading after delivery of baby.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
measure systolic arterial blood pressure changes after spinal anesthesia.
Periodo de tiempo: immediately after spinal anesthesia
|
immediately after spinal anesthesia
|
|
Total ephedrine dose or phenylephrine dose /milligram.
Periodo de tiempo: throughout the operation
|
throughout the operation
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- 9/2026 ANET 53
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .